The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease

New England Journal of Medicine

Volumn 350, Issue 10, 2004, Pages 1005-1012

  Celli, Bartolome R ^a,g   Cote, Claudia G ^b   Marin, Jose M ^c   Casanova, Ciro ^d   Montes De Oca, Maria ^e   Mendez, Reina A ^e   Plata, Victor Pinto ^a   Cabral, Howard J ^f  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Bay Pines VA Medical Center   (United States)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^e HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^g ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; OXYGEN; SALBUTAMOL;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEATH; DISEASE SEVERITY; DYSPNEA; EXERCISE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RATING SCALE; RISK; SMOKING; SURVIVAL; VALIDATION PROCESS;

AGED; AIRWAY OBSTRUCTION; BODY MASS INDEX; DYSPNEA; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 1442306237     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021322     Document Type: Article

References (35)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
2. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349: 1269-76.
3. Definitions, epidemiology, pathophysiology, diagnosis, and staging. Am J Respir Crit Care Med 1995;152:Suppl:S78-S83.
4. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398-420.
5. Nocturnal Oxygen Therapy Trial Group. Continuous of nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial. Ann Intern Med 1980; 93:391-8.
6. Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease: a clinical trial. Ann Intern Med 1983; 99:612-20.
7. Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ, ZuWallack RL. Variables related to increased mortality following outpatient pulmonary rehabilitation. Eur Respir J 1996;9:431-5.
8. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002;121:1434-40.
9. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791-7.
10. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160: 1856-61.
11. American Thoracic Society Statement. Lung function testing: selection of reference values and interpretative strategies. Am Pev Respir Dis 1991;144:1202-18.
12. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
13. Mahler D, Wells C. Evaluation of clinical methods for rating dyspnea. Chest 1988;93: 580-6.
14. Charlson M, Szatrowski T, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51.
15. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997;127:1072-9.
16. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000;117:662-71.
17. Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115:635-41.
18. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133: 14-20.
19. Burrows B. Predictors of loss of lung function and mortality in obstructive lung diseases. Eur Respir Rev 1991;1:340-5.
20. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
21. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:785-90.
22. Szekely LA, Oelberg DA, Wright C, et al. Preoperative predictors of operative morbidity and mortality in COPD patients undergoing bilateral lung volume reduction surgery. Chest 1997;111:550-8.
23. Shah M, Hasselblad V, Gheorgiadis M, et al. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic and nonischemic cardiomyopathy. Am J Cardiol 2001;88:987-93.
24. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92.
25. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997;155:1278-82.
26. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997;10: 417-23.
27. Cox DR. Regression models and life-tables. J R Star Soc [B] 1972;34:187-220.
28. Harrell FE Jr, Lee KL, Mark DB. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
29. Nam B-H, D'Agostino R. Discrimination index, the area under the ROC curve. In: Huber-Carol C, Balakrishnan N, Nikulin MS, Mesbah M, eds. Goodness-of-fit tests and model validity. Boston: Birkhäuser, 2002: 273-7.
30. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-303.
31. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:680-5.
32. Pulmonary rehabilitation - 1999. Am J Respir Crit Care Med 1999;159:1666-82.
33. Ries AL, Kaplan RM, Blumberg E. Use of factor analysis to consolidate multiple outcome measures in chronic obstructive pulmonary disease. J Clin Epidemiol 1991;44: 497-503.
34. Mahler DA, Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;145:467-70.
35. Wegner RE, Jorres RA, Kirsten DK, Magnussen H. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur Respir J 1994; 7:725-9.